ReviewJournal of industrial microbiology & biotechnology2013
Microbial natural products: molecular blueprints for antitumor drugs.
Review in Journal of industrial microbiology & biotechnology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Broad-Spectrum Antibacterial Action of Lipopeptides Derived from Bacillus smithii by Targeting Quorum Sensing.Probiotics and antimicrobial proteins · 2026Article
- An enhanced domestication method for uncultured bacteria.ISME communications · 2026Article
- iCASRED, a scarless DNA editing tool inSynthetic and systems biotechnology · 2025Article
- Article
- Naphthoquinone Derivatives fromMolecules (Basel, Switzerland) · 2024Article
- A proteomic landscape of pharmacologic perturbations for functional relevance.Journal of pharmaceutical analysis · 2024Article
- Analogues of Anticancer Natural Products: Chiral Aspects.International journal of molecular sciences · 2023Review
- Microbial Metabolites as Ligands to Xenobiotic Receptors: Chemical Mimicry as Potential Drugs of the Future.Drug metabolism and disposition: the biological fate of chemicals · 2023Review
- Chrysophanol-Induced Autophagy Disrupts Apoptosis via the PI3K/Akt/mTOR Pathway in Oral Squamous Cell Carcinoma Cells.Medicina (Kaunas, Lithuania) · 2022Article
- Antibacterial activities of plant-derived xanthones.RSC medicinal chemistry · 2022Review
- Stress Dependent Biofilm Formation and Bioactive Melanin Pigment Production by a ThermophilicPolymers · 2022Article
- Natural Compounds as Therapeutic Agents: The Case of Human Topoisomerase IB.International journal of molecular sciences · 2021Review
- Anticancer Drug Discovery from Microbial Sources: The Unique Mangrove Streptomycetes.Molecules (Basel, Switzerland) · 2020Review
- Crystal Structures of theThe Plant cell · 2020Article
- Natural Bioactive Thiazole-Based Peptides from Marine Resources: Structural and Pharmacological Aspects.Marine drugs · 2020Review
- Article
- A Review of the Microbial Production of Bioactive Natural Products and Biologics.Frontiers in microbiology · 2019Review
- Ergosterol peroxide from marine fungus Phoma sp. induces ROS-dependent apoptosis and autophagy in human lung adenocarcinoma cells.Scientific reports · 2018Article
- Quinohemanine, a quinoxalinone-bohemamine hybrid compound from Streptomyces sp. CPCC 200497.The Journal of antibiotics · 2018Article
- Synthetic biology, genome mining, and combinatorial biosynthesis of NRPS-derived antibiotics: a perspective.Journal of industrial microbiology & biotechnology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbes from two of the three domains of life, the Prokarya, and Eukarya, continue to serve as rich sources of structurally complex chemical scaffolds that have proven to be essential for the development of anticancer therapeutics. This review describes only a handful of exemplary natural products and their derivatives as well as those that have served as elegant blueprints for the development of novel synthetic structures that are either currently in use or in clinical or preclinical trials together with some of their earlier analogs in some cases whose failure to proceed aided in the derivation of later compounds. In every case, a microbe has been either identified as the producer of secondary metabolites or speculated to be involved in the production via symbiotic associations. Finally, rapidly evolving next-generation sequencing technologies have led to the increasing availability of microbial genomes. Relevant examples of genome mining and genetic manipulation are discussed, demonstrating that we have only barely scratched the surface with regards to harnessing the potential of microbes as sources of new pharmaceutical leads/agents or biological probes.
Indexed as
Identifiers
23999966What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.